Brazil Overhauls Obesity Drug Guidance as FDA Approves Lilly’s Daily Pill

Overview

• The FDA approved Eli Lilly’s daily obesity pill Foundayo on Wednesday, expanding oral treatment options in the United States.
• Company trials reported average weight loss of about 12% to 15%, and the tablet can be taken at any time with or without food.
• Lilly says U.S. sales start April 6 at $149 for the lowest dose, with Medicare expected to cover some patients as private plans weigh inclusion.
• In Brazil, Abeso published a 32‑point pharmacologic guideline on Tuesday that brings GLP‑1 drugs into routine care, urges earlier personalized use with lifestyle support, and favors higher‑potency options when feasible.
• The Brazilian guideline sets drug criteria at BMI ≥30 or at ≥27 with weight‑related conditions, allows case‑by‑case use for abdominal adiposity with complications, and warns against compounded or falsified products as the SUS still lacks national coverage.